摘要:
Solid forms comprising a compound useful in the treatment, prevention and management of various conditions and diseases are provided herein. In particular, the invention provides solid forms comprising (−)—O-desmethylvenlafaxine, including salts thereof, having utility for the treatment, prevention and management of conditions and disorders including, but not limited to, affective disorders such as depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinson's disease, epilepsy, cerebral function disorders, obesity and weight gain, incontinence, dementia and related disorders.
摘要:
Provided herein are pharmaceutical compositions comprising transnorsertraline, salts and polymorphic forms of transnorsertraline, methods of making the compositions, and methods for their use for the treatment of CNS diseases, including depression.
摘要:
A pharmaceutical formulation comprising ##STR1## as the active ingredient, polyethylene glycol, NaOH, and water, wherein the mole equivalents of NaOH per mole equivalent of active ingredient is at least about 1.1, is suitable for soft gelatin capsule filling.
摘要:
A method for preparing pharmaceutical formulations of poorly soluble drug substances in the form of concentrated solutions for filling soft gelatin capsules and solid dispersions and suspensions for filling hard gelatin capsules and compressing into tablets is provided. Pharmaceutical formulations of poorly soluble drug substances are also disclosed. The formulations include the sodium salt of the poorly soluble drug substance, a conversion aid such as PEG, polysorbate, a sugar alcohol (e.g. mannitol or xylitol), propylene glycol or transcutol, and, in some cases an excipient, such as dicalcium phosphate dihydrate, lactose monohydrate, or microcrystalline cellulose.
摘要:
Disodium tiludronate tetrahydrate is provided for use in pharmaceutical compositions for oral administration in the form of a tablet, effervescent composition, capsule and the like.
摘要:
Provided herein are pharmaceutical compositions comprising transnorsertraline, salts and polymorphic forms of transnorsertraline, methods of making the compositions, and methods for their use for the treatment of CNS diseases, including depression.
摘要:
A pharmaceutical suspension formulation comprising 0.1 to 40% by weight ##STR1## as the active ingredient; 0.1 to 40% by weight Transcutol; 0.1-99% by weight starch; 0-40% by weight polyethylene glycol, NaOH and water, wherein the mole equivalents of NaOH per mole equivalent of active ingredient is from 0.5 to 1.5 is particularly useful for filling hard gelatin capsules.